How are companies influenced by the current crisis and what are their most common commercial challenges? How can commercial excellence play a crucial role in defining the right actions to mitigate and avoid negative impacts on bottom line results?
Edition 1/2020: How restaurants and food service companies can boost their revenues and occupancy, with the effective use of data analytics
Food Away From Home (AFH) sales in the European Union have reached almost € 600 billion per year; figures that increase year over year and that represent approximately 7-7.5% of the overall European expenses.
The industry is rushing, bringing new players in the field, facilitating consolidation, showing a fostering trend of internationalization similar to the one already experimented in the fashion industry. But with millions of customers eating out or ordering online every day, where does the industry stand in the use of data, to support its growth?
This paper aims to define a possible project plan that companies in the food industry can follow to deliver immediate revenue benefits to their business and enable their companies to compete in a more and more sophisticated battlefield.
The EPP® Thought Leadership Series provide insights from pricing leaders around the globe. When a new insight breaks, these pricing leaders already think of the unanswered questions and the story behind the story. These people want to inspire you to act - to take the next step in your journey. With these series, we help to take the right actions
Edition 1/2019 : The evolving landscape of Biosimilars and it”s impact on the public procurement and Tendering environment
Highpoint, an IQVIA company, has conducted various analysis to assess the impact of tenders for biosimilars and observed recent market trends as well as manufacturer behaviors to capture the subtle changes. Our findings translate into a comprehensive view on how companies could improve their bidding and tender strategy to succeed in this space. lastly, we provide our outlook on this topic emphasizing the importance for all stakeholders to find the right balance between cost containment for payers and sustainability for manufacturers to ensure that ultimately, patients and physicians will have multiple treatment options available.
The EPP® Thought Leadership Series provide insights from pricing leaders around the globe. When a new insight breaks, these pricing leaders already think of the unanswered questions and the story behind the story. These people want to inspire you to act - to take the next step in your journey. With these series, we help to take the right actions.
With 25% of the pharmaceutical market worldwide going through some form of T&C, you are far from alone. We expect, in both developed and emerging countries that trend to not only continue, but increase. Consequently, the importance for Life Sciences companies to build a succesful tendering and contracting governance globally increases as well.
With public procurement growing across industries, Life Sciences companies are no exception to the rule. Indeed, 25% of the pharmaceutical market is now considered to be traded through some form of tender. Tenders are a specific form of centralized procurement where government or any level of health authorities are enforcing competition for a product.
The third volume in the Handbooks in Health Economic Evaluation series, this book provides the reader with a comprehensive set of instructions and examples of how to perform an economic evaluation of a health intervention. It focuses solely on cost-effectiveness analysis in health care. The book is developed out of the Advanced Methods in Economic Evaluation course taught at the University of Oxford, and the four main sections mirror the four principal components of the course: Outcomes, Costs, Modelling using decision trees and Markov models, and Presenting cost-effectiveness results.
Series editors Alastair Gray and Andrew Briggs